Pasar al contenido principal

PE37: Ensayo clínico aleatorizado multicéntrico de cribado con sFlt1/PlGF e inducción selectiva del parto para la prevención de preeclampsia a término.

PI22/00109

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Centro realización INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term, protocol of the PE37 study

  • Llurba, Elisa|||0000-0003-4048-6407
  • Crispi, Fatima|||0000-0002-7422-5240
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Youssef, Lina|||0000-0002-0554-5507
  • Delgado, Juan Luis
  • Puig, Isabel
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Krofta, Ladislav
  • Mackova, Katerina
  • Martinez-Varea, Alicia
  • Tubau Navarra, Albert|||0000-0001-5460-0763
  • Ruiz, Aina
  • Paya, Antoni
  • Prat Grau, Maria|||0000-0002-3811-9205
  • Chantraine, Frederic
  • Comas, Carmina|||0000-0001-6631-0165
  • Kajdy, Anna
  • Lopez-Tinajero, Maria Fernanda|||0000-0002-3999-2620
  • Figueras, Francesc|||0000-0003-4403-1274
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Castillo, Heidi
  • Casas, Irene
  • Campos, Rafael José
  • Timmermans, Marie
  • Parriego, Vanessa
  • Sys, Dorota
  • Modzelewski, Jan
Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of.